NCT00139698已完成3 期
A Phase III, Multicenter, Open-Label, Dose-Titrating, 16-Week Study Evaluating The Efficacy, Tolerability and Safety of Olmesartan Medoxomil 20 Mg and 40 Mg Alone or in Combination With 12.5 Mg to 25 Mg of Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 410
- 试验地点
- 32
- 主要终点
- Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
研究概览
简要总结
Efficacy, tolerability and safety of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has mild to moderate hypertension
排除标准
- •History of secondary hypertension
结局指标
主要结局
Efficacy of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
次要结局
- Safety and tolerability of olmesartan alone or in combination with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
研究者
研究点 (32)
Loading locations...
相似试验
已完成
3 期
Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in HypertensionEssential HypertensionNCT00902538Daiichi Sankyo2,204
已完成
4 期
An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With HypertensionHypertensionNCT00185068Daiichi Sankyo110
已完成
2 期
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential HypertensionHypertensionNCT00153049Boehringer Ingelheim583
已完成
4 期
18 Week Study Evaluating Safety and Efficacy of Olmesartan, Amlodipine, and Hydrochlorothiazide, in Type 2 DiabeticsHypertensionType 2 DiabetesNCT00654745Daiichi Sankyo207
已完成
4 期
PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)HypertensionNCT00274638Boehringer Ingelheim805